What is the effect of NMN for APOE4 carriers?
NMN is being tracked against this question, but Phoenix has not yet published a ranked result for this exact question.
Browse by intervention
One intervention, every measured benefit and result that did not improve. See who it moved for, where it stayed neutral or went the other way, and the next hypothesis Phoenix can validate.
How to read this
Observational research: real APOE4 carriers tracked over time, each compared with their own earlier self. Members chose their interventions, with no randomisation or placebo group. Everything else they changed is shown beside each result.
Read the full methods and limitsNMN is being tracked against this question, but Phoenix has not yet published a ranked result for this exact question.
Collecting evidence
NMN is being tracked against this question, but Phoenix has not yet published a ranked result for this exact question.
Every carrier who logs a dated start and a repeat test moves this page closer to an answer, including you.
Get an email when Phoenix publishes a meaningful update. At most one combined update each week.
NMN and NR raise NAD+ in the blood, and small trials suggest they may slightly improve sleep quality or general well-being. Trials in people with memory complaints have not shown better memory, and the cancer concern comes from animal studies, so long-term safety in people is simply unknown. Too early to call them brain protection.
APOE4-specific evidence: none
NMN and NR reliably raise NAD+ and may help sleep or well-being a little, but trials so far show no clear memory benefit and long-term safety is untested.
Morifuji 2024, GeroscienceGrade B
Older adults: NMN raised blood NAD and improved sleep quality versus placebo.
Read on PubMed (opens in a new tab)Yi 2023, GeroscienceGrade B
Healthy middle-aged adults: NMN raised NAD and improved a general health score; industry-funded.
Read on PubMed (opens in a new tab)Wu 2025, Alzheimers Dement (N Y)Grade C
Crossover trial in 46 people with memory complaints: p-tau217 fell 7% on NR versus an 18% rise on placebo; no change in cognitive tests.
Read on PubMed (opens in a new tab)Martens 2026, Alzheimers DementGrade C
Pilot trial in mild cognitive impairment: NR doubled blood NAD+ but did not improve cognition over 12 weeks.
Read on PubMed (opens in a new tab)Chen 2024, Curr Diab RepGrade C
Meta-analysis of 8 trials: NMN did not significantly change glucose or lipid markers.
Read on PubMed (opens in a new tab)Chaubey 2026, Cell Rep Med
Animal or lab study
Mouse study: P7C3-A20, which restores NAD+ balance, reversed advanced Alzheimer-like disease in mice.
Read on PubMed (opens in a new tab)5 passages with a caution, 1 also discussed
Now showing: Dr. Kevin Tran · 5:37
Open on YouTube (opens in a new tab)
Researchers warn NAD+ boosters may overshoot in animals.
“over-the-counter NAD+ precursor have been shown in animal models to raise cellular NAD+ to dangerously high levels”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier

NMN and NR skip the body's NAD+ safety brake.
“OTC precursors like NMN and NR bypass this regulation entirely potentially flooding cells with more NAD+ than they can safely handle”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier

Talk to your doctor before continuing NMN or NR.
“the long-term safety data simply doesn't exist yet”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier

Review NMN or NR with your doctor given safety warnings.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)
Researchers warn NMN and NR may push NAD+ too high.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)NR lowered p-tau217 in a short trial; safety unknown.
“One study showed that eight weeks of NR treatment significantly reduce [p-tau217] concentration which is a key Alzheimer's biomarker compared to placebo.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Last reviewed
Search by health goal or intervention to see what changed for real members, including results that moved the wrong way.
Want to try NMN and see whether it works for you? Phoenix tracks it beside your labs and how you feel.
Apply to join PhoenixNMN · 1 outcome shown.
LDL cholesterol: Decrease 26.3 %
Cases: 1
Context affected
NMN
?Collecting evidenceOne clean curated NMN case lowered LDL cholesterol 26.3% in 42 days; paired values were not published.
Not explained by the science yetNMN human trials target NAD+, insulin sensitivity and vascular measures; none establish an LDL-lowering mechanism.
Collecting evidence
NMN is being tracked against LDL cholesterol, but Phoenix has not yet published a ranked result for this exact question.
Every carrier who logs a dated start and a repeat test moves this page closer to an answer, including you.
Get an email when Phoenix publishes a meaningful update. At most one combined update each week.
Context affected this result: Not printed as of Release 001: no known mechanism links NMN to LDL cholesterol. This case is not included in the printed cases or test-next list.
The 43-page study: what members tried, how their bloodwork and wearable results changed, and what else changed alongside them.
Turn evidence into your next test
476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.
Full research index
Choose an outcome, like LDL cholesterol or sleep, or an intervention, like training: both paths open the same measured records.